Patients ( aged 12 years ) with acute bacterial skin and skin-structure infections ( cellulitis or erysipelas , major cutaneous abscess , or wound infection ) that had a minimum lesion area of 75 cm ( 2 ) and were suspected or documented to be associated with a Gram-positive pathogen , were randomly assigned ( 1:1 ) , via an interactive voice-response system with block randomisation , to receive intravenous once-daily tedizolid ( 200 mg for 6 days ) or twice-daily linezolid ( 600 mg for 10 days ) , with optional oral step-down .